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Abstract
Background: A range of molecular amplification techniques have been developed for the diagnosis of Human African
Trypanosomiasis (HAT); however, careful evaluation of these tests must precede implementation to ensure their high clinical
accuracy. Here, we investigated the diagnostic accuracy of molecular amplification tests for HAT, the quality of articles and
reasons for variation in accuracy.
Methodology: Data from studies assessing diagnostic molecular amplification tests were extracted and pooled to calculate
accuracy. Articles were included if they reported sensitivity and specificity or data whereby values could be calculated. Study
quality was assessed using QUADAS and selected studies were analysed using the bivariate random effects model.
Results: 16 articles evaluating molecular amplification tests fulfilled the inclusion criteria: PCR (n=12), NASBA (n=2), LAMP
(n=1) and a study comparing PCR and NASBA (n=1). Fourteen articles, including 19 different studies were included in the
meta-analysis. Summary sensitivity for PCR on blood was 99.0% (95% CI 92.8 to 99.9) and the specificity was 97.7% (95% CI
93.0 to 99.3). Differences in study design and readout method did not significantly change estimates although use of
satellite DNA as a target significantly lowers specificity. Sensitivity and specificity of PCR on CSF for staging varied from
87.6% to 100%, and 55.6% to 82.9% respectively.
Conclusion: Here, PCR seems to have sufficient accuracy to replace microscopy where facilities allow, although this
conclusion is based on multiple reference standards and a patient population that was not always representative. Future
studies should, therefore, include patients for which PCR may become the test of choice and consider well designed
diagnostic accuracy studies to provide extra evidence on the value of PCR in practice. Another use of PCR for control of
disease could be to screen samples collected from rural areas and test in reference laboratories, to spot epidemics quickly
and direct resources appropriately.
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Introduction
Human African trypanosomiasis (HAT), also known as sleeping
sickness, is a parasitic disease caused by single-celled, eukaryotic
protozoa called trypanosomes. Two subspecies of Trypanosoma
brucei namely T. b. gambiense and T. b. rhodesiense, cause the disease
in West and Central Africa and in East Africa respectively [1]. In
recent years the number of HAT patients has fallen due to the
renewal of control programs in the late 1990’s; however the
current number of patients reported for treatment per year in
Africa is still approximately 10,000; with an estimated number of
infected patients around three times that number [1]. The
reference standard diagnostic test for HAT is microscopy, whereby
demonstration of parasites in the body fluids confirms active
infection [2,3]. Microscopy is a compelling diagnostic tool due to
its high specificity, ease of use, lack of cold chain, lack of electricity
requirements and hence ability to be taken into rural areas where
HAT is prevalent. However, its lack of sensitivity (approximately
10,000 parasites/ml for wet blood film examination) means that
many patients may not be positively diagnosed (false negative)
which may lead to death of patients in the absence of treatment
[2]. Only with concentration methods such as microhaematocrit
centrifugation [3], quantitative buffy coat technique (QBC) [4]
and mini-anion-exchange centrifugation technique (mAECT)
[5,6] can microscopy detect parasitaemia as low as 50 parasites/
ml. This limits the utility of microscopy in resource-poor settings,
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laboratory logistics. Regardless, microscopy still remains the basis
of HAT diagnosis, disease staging and after-treatment follow-up
due to its high specificity and availability.
HAT comprises two stages of disease; stage one affects the
blood, lymph and peripheral organs; stage two occurs when
parasites enter the central nervous system. Currently, staging of
HAT is performed by microscopic examination of cerebrospinal
fluid (CSF) for presence of parasites and an increased white blood
cell (WBC) count (WHO 1986). Patients with stage one HAT
should be treated with pentamidine (T. b. gambiense) or suramin (T.
b. rhodesiense) [7]. Stage two drugs must be able to cross the blood
brain barrier (BBB); melarsoprol is a commonly administered drug
for treatment of this stage but can cause reactive encephalopathy
with sometimes fatal outcome [8]. The newly recommended
treatment for stage two T.b. gambiense HAT, i.e. nifurtimox-
eflornithine combination is less toxic but administration is still
complex [9]. It is therefore, crucial to reduce false positives and,
subsequently also, determine the appropriate treatment by
accurate disease stage determination.
Recently, a range of molecular amplification techniques have
been developed for the diagnosis of HAT, with polymerase chain
reaction (PCR) at the forefront [10–12]. These tests are not
commonly used in endemic areas due to the necessity of
continuous electricity, trained staff, sophisticated equipment, and
the requirement of a cold chain. Isothermal reactions such as loop-
mediated isothermal amplification (LAMP) [13,14] and nucleic
acid sequence-based amplification (NASBA) [15,16] have also
been proposed for the diagnosis of HAT. These diagnostic tests
may be more applicable for HAT diagnosis because they need less
expensive equipment and post-amplification handling require-
ments that are imposed by PCR testing. If the available molecular
amplification diagnostic tests are to be safely used to support HAT
diagnosis, they must have high diagnostic specificity as well as
sensitivity to ensure that the dangers of inappropriate treatment
are avoided.
As laboratory strengthening in endemic areas increases, it is
expected that the applicability of molecular tests will increase.
However, careful evaluation of these tests against the current
reference standard, microscopy, must precede implementation.
Therefore, we have investigated the published diagnostic accuracy
of molecular amplification tests for HAT compared to microscopy
for both initial diagnosis as well as for disease staging.
Furthermore, we investigated reasons for variation in accuracy
amongst HAT diagnostic tests.
Materials and Methods
Searching
In order to find all relevant articles assessing the diagnostic
accuracy of molecular assays for HAT, MEDLINE and EMBASE
databases were searched with a combination of the following
search terms as MeSH (Medical Subject Headings) terms and/or
free text words; see Appendix S1. Abstracts of study articles
published until the 4
th March 2011 were identified electronically
in Medline and Embase. Unpublished data were sought from
scientific conference abstract books, symposia, books and experts
(Institute of Tropical Medicine, Antwerp, Belgium; Makerere
University Kampala, Uganda and Centre International de
Recherche-De ´velopement sur l’Elevage en Zone Humide, Bobo
Dioulasso, Burkina Faso). The reference lists of included studies
and of review articles were checked to identify additional studies
for inclusion.
Articles were initially screened on the title and secondly upon
reading the abstract. At this stage, articles not using molecular
techniques for diagnostic purposes, case-studies (only patients with
confirmed HAT), review articles, serological diagnostics studies
and studies only diagnosing animal trypanosomiasis or other non-
HAT trypanosomes were excluded. All studies highlighted by at
least one of the two review authors were selected; if either reviewer
was unsure about exclusion then the article was included to the
next stage. The full text of appropriate articles was read and taken
forward for study selection. Study selection was conducted by two
authors (CM and EA) independently, in the case of disagreements
a third author (either KB or ML) acted as a mediator.
Selection
We included all studies that evaluated the accuracy of molecular
tests for either HAT, for one of the two subspecies of trypanosomes
(i.e. East Africa or Central and Western Africa), or for stage two
HAT. Studies were included if they involved clinical specimens of
patients suspected of any form of HAT and fulfilled the following
inclusion criteria:
– Any study design (case-control, consecutive and cross-sectional
studies), as long as the study involved human clinical samples
and both diseased and non-diseased patients.
– The use of the reference standard, microscopy of trypanosomes
in blood or cerebrospinal fluid (CSF) or lymph node aspirate.
Differentiation between different microscopic techniques was
not made, although taken into account during the quality
assessment of the articles.
Data abstraction
Diagnostic accuracy data for two-by-two contingency tables,
patient spectrum data and quality assessment data were extracted
by two independent review authors (CM and EA) and recorded
onto a standard form. Discrepancies were resolved by mediation of
a third researcher (ML). From each study, the following
characteristics were extracted: i) molecular test type; ii) clinical
material assessed (blood, cerebrospinal fluid; iii) the sub-species
detected (T.b. gambiense or T.b. rhodesiense); iv) read-out method of
Author Summary
A range of molecular amplification techniques has been
developed for the diagnosis of HAT, with polymerase chain
reaction (PCR) at the forefront. As laboratory strengthening
in endemic areas increases, it is expected that the
applicability of molecular tests will increase. However,
careful evaluation of these tests against the current
reference standard, microscopy, must precede implemen-
tation. Therefore, we have investigated the published
diagnostic accuracy of molecular amplification tests for
HAT compared to microscopy for both initial diagnosis as
well as for disease staging.
Here, PCR tests seem to have an acceptably high specificity
and sensitivity for diagnosis of stage I HAT. This conclusion
is, however, based on multiple-microscopy based tech-
niques as reference standards, which may have low
sensitivity, and a patient population that was not always
representative. Future studies should, therefore, first and
foremost include those patients for which PCR may
become the test of choice. More certainty about the
practical value of PCR tests for HAT diagnosis should come
from non-accuracy design studies, like feasibility or cost-
effectiveness studies.
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index test; vi) study design i.e. whether the patients were equally
suspected (‘consecutive design’) or if cases and controls were
selected from different populations (‘case-control study’). Quality
assessment was based on QUADAS (Quality Assessment of
Diagnostic Accuracy Studies) [17].
Quantitative data synthesis
The estimates of sensitivity and specificity and their 95%
confidence interval were plotted in forest plots and receiver
operating characteristic (ROC) space in Review Manager version
5. For the meta-analysis, we used the bivariate random effects
model through Proc NLMIXED in SAS for Windows, version 9.2
(Cary, NC). This model pools sensitivity and specificity in one
model, while accounting for the correlation between the two [18].
Studies that evaluated the diagnostic value of the tests were
analyzed separately from studies that evaluated the staging value
of the tests. Articles in which two-by-two contingency tables could
not be completed were excluded from the meta-analyses.
Summary estimates of sensitivity and specificity for diagnosis
and staging for the different assays were calculated. Meta-analysis
was performed if at least three studies evaluated the same assay in
the same sample type (either blood or CSF). Real-time assays were
considered as different assays than standard assays, because of
significant differences in protocol and design of primer/probe
mixes.
The results in diagnostic accuracy reviews are expected to show
much heterogeneity, mainly due to threshold effects. It is therefore
more common to investigate the sources of heterogeneity, without
formally testing whether heterogeneity is present or not [19]. For
the same reasons, a standard random effects model was used.
Heterogeneity was investigated by adding the following covariates
to the meta-regression models, if appropriate and possible: i) type
of detection system; ii) tissue used e.g. blood versus CSF; iii) sub-
species detection T.b. gambiense or T.b. rhodesiense; iv) target gene of
the index test; v) study design and quality indicated by consecutive
versus case-control studies.
All reporting in this review is in accordance with the MOOSE
guidelines [20].
Results
Flow of included studies
The electronic searches yielded a total of 282 articles (see
Figure 1). After reading the title and abstract, thirty-six articles
were taken forward and the full text article was read. Twenty
articles were excluded at this stage; 4 articles used molecular
methods for other purposes e.g. genotyping data, 5 articles did not
test patient samples and 11 articles reported case series where the
specificity could not be calculated. Sixteen articles were selected
for inclusion in the systematic review.
Study characteristics
The index tests assessed were; PCR (n=12) [11,21–31],
NASBA (n=2) [15],[16], LAMP (n=1) [13] and a study
comparing PCR and NASBA (n=1) [23]. Two studies assessed
PCR combined with Oligochromatography (PCR-OC) and three
studies assessed NASBA combined with Oligochromatography
(NASBA-OC). One study [15] assessed a real-time NASBA assay
(RT-NASBA).
Ten publications focused on the primary diagnosis of HAT in
blood, one of these used CSF and blood for diagnosis of HAT.
Two publications reported on both diagnosis and staging and used
blood for diagnosis and CSF for staging. The two publications
focusing only on staging both used CSF for this purpose. See
Table 1 for full details.
Quality of study reports
All articles were scored with the QUADAS tool (quality
assessment for diagnostic accuracy) which included, amongst
other, scoring based upon patient spectrum, blinding, exclusion
and inclusion criteria (Figure 2). Studies performed badly when
assessed for using representative patient populations. The majority
of the studies seemed to enroll their patients in a consecutive way,
although they did select them from highly skewed populations: in
most articles, patients with confirmed HAT were enrolled, after
which these patients underwent both the reference standard
(microscopy) and the index test. This could artificially increase the
clinical accuracy of tests. Only seven out of 16 articles included a
representative patient spectrum, that is, patients suspected of
infection with HAT.
In addition, all studies were scored ‘unclear’ when assessed for
blinding of the reference standard to the index test results and vice
versa (items 10 and 11 of QUADAS). There is a chance of bias if
readers had prior knowledge of either the index or reference test
outcome. The verification process (items 3 to 7 of QUADAS)
raised no problems in most of the articles and the execution of the
index test was sufficiently described (item 8) in all articles except
one [30]. The aspect of withdrawals (item 14) was not applicable
for most of the studies; 2 articles explained the withdrawal of
patients from the study (Figure 2).
Accuracy of molecular amplification tests for diagnosing
HAT
Two publications did not report sufficient data to construct the
complete 262 tables, so these were excluded from the meta-
analyses [13,32]. The ten papers that reported on the accuracy of
molecular tests for the diagnosis of HAT, included 15 separate
studies and their respective, complete 262 tables. Their
sensitivity varied from 82% to 100% and the specificity ranged
from 59% to 100% (Figure 3). Eleven studies analysed PCR or
PCR-OC in blood; their pooled sensitivity was 99.0% (95% CI
92.8 to 99.9%) and the pooled specificity was 97.7% (95% CI
93.0 to 99.3%) (Figure 4). There was no significant difference
between the clinical accuracy of PCR and PCR-OC performed
on blood samples (Table 2). Two studies assessed NASBA-OC,
their sensitivities were 90.2% and 97.2%; their specificities were
98.9% and 59.3% respectively. The only study evaluating
NASBA-RT in blood had a sensitivity of 93.9% and a specificity
of 61.5%.
Investigation of heterogeneity
The largest group of studies evaluated PCR (including PCR-
OC) on blood. It was performed on five different targets: T.
gambiense specific glycoprotein (TgsGP) [27,31], serum resistance
associated gene (SRA) [27], expression-site–associated genes 6 and
7 (ESAG 6/7) [11], 18S ribosomal DNA [23,23] and the satellite
DNA [26,28–30]. Target genes differ in copy number from TgsGP
and SRA as single copy targets, ESAG with 10 copies, 18S rDNA
with 40–200 copies and the satellite DNA with approximately
10,000 copies. We compared satellite sequences versus the other
target sequences, which showed that using the satellite sequences
as a target had a significantly lower specificity (p=0.002, see
Table 2).
Another source of heterogeneity is the infecting sub-species (T.b.
rhodesiense or T.b. gambiense) as patients with T.b.g usually have a
lower parasitaemia than patients with T.b.r. In addition, detection
Molecular Diagnostics for HAT—Systematic Review
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that may appear in both sub-species also changes the diagnostic
accuracy. Of the 11 PCR studies conducted on blood, one
amplified T. b. rhodesiense-specific genes [27] and two amplified T.
b. gambiense-specific genes [27,31]. The remaining nine studies
were species-specific amplifying T. brucei s.l., thus amplifying the
genes from both subspecies. The advantage of this method is that
it is known to increase sensitivity. A separate analysis of the seven
studies in patients infected with T. b. gambiense, using a PCR
detecting both subspecies revealed a sensitivity of 97.6% (95% CI
90.8 to 99.4%) and a specificity of 95.8% (95% CI 88.9 to
98.5%).
Figure 1. Flow of included studies.
doi:10.1371/journal.pntd.0001438.g001
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Publication (reference) Aim Index test Region Country
Infecting
Subspecies
Clinical
sample Study design
Kabiri et al., 1999 [11] Diagnosis PCR CWA Equatorial Guniea,
Angola
T.b.gambiense Blood Consecutive
Truc et al., 1999 [24] Staging PCR CWA Cote d’Ivoire T.b.gambiense CSF Consecutive
Kyambadde et al., 2000 [28] Diagnosis PCR CWA Uganda T.b.gambiense Blood & CSF Consecutive
Penchenier et al., 2000 [30] Diagnosis PCR CWA Cameroon T.b.gambiense Blood Consecutive
Radwanska et al., 2002 [31] Diagnosis PCR CWA Cote d’Ivoire T.b.gambiense Blood Consecutive
Solano et al., 2002 [26] Diagnosis PCR CWA Central Cote d’Ivoire T.b.gambiense Blood Consecutive
Jamonneau et al. 2003 [25] Staging PCR CWA Central Cote d’Ivoire T.b.gambiense CSF Consecutive
Becker 2004 [32] Development
studies
RT-PCR CWA South Sudan T.b.gambiense Blood Case series
Picozzi et al., 2005 [27] Diagnosis PCR CWA & EA South Sudan,
North-West Uganda
T.b.gambiense &
rhodesiense
Blood Case control
Deborggraeve
et al., 2006 [21]
Diagnosis PCR-OC CWA D.R. Congo T.b.gambiense Blood Case control
Koffi et al., 2006 [29] Diagnosis PCR CWA Central Cote d’Ivoire T.b.gambiense Blood Consecutive
Njiru et al., 2007 [13] Development
studies
LAMP CWA & EA Uganda, Tanzania T.b.gambiense &
rhodesiense
Blood & CSF Case series
Mugasa et al., 2008 [15] Diagnosis NASBA-RT EA Uganda T.b.rhodesiense Blood Case Control
Mugasa et al., 2009[16] Diagnosis
and staging
NASBA-OC CWA & EA D.R.Congo, Uganda T.b.gambiense &
rhodesiense
Blood & CSF Case control (blood);
Consecutive (CSF)
Matovu et al., 2010 [23] Diagnosis PCR-OC &
NASBA-OC
CWA & EA D.R.Congo, Uganda T.b.gambiense &
rhodesiense
Blood Case control
Deborggraeve
et al., 2011 [22]
Diagnosis
and staging
PCR CWA D.R. Congo T.b.gambiense CSF Case control (blood);
Consecutive (CSF)
CWA=Central and West Africa; EA=East Africa. Development study=article in which protocol is developed. PCR=Polymerase Chain Reaction; RT-PCR=Real-time PCR;
PCR-OC=PCR-oligochromatography; LAMP=Loop-mediated isothermal amplification; NASBA=Nucleic acid sequence based amplification; NASBA-RT=Real-time
NASBA. CSF=Central Spinal Fluid.
doi:10.1371/journal.pntd.0001438.t001
Figure 2. QUADAS results.
doi:10.1371/journal.pntd.0001438.g002
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Of the 11 PCR studies on blood, six were diagnostic accuracy
studies that enrolled consecutive suspects, the other five were case-
control studies. The non case-control studies showed a pooled
sensitivity of 98.6% (95% CI 90.7 to 99.8%) and a pooled
specificity of 94.5% (95% CI 86.8 to 97.8%). In the case-control
studies, the pooled specificity was significantly higher: 99.8% (95%
CI 95.5 to 100%). The sensitivity did not significantly differ
between the different types of study design: 98.7% (95% CI 82.9 to
99.9%). See also Table 2.
Accuracy of molecular amplification tests for staging HAT
Four studies evaluated the accuracy of molecular tests to
differentiate between stage one and stage two HAT. Three of these
evaluated PCR in CSF while one evaluated NASBA-OC. The
sensitivity of the PCR tests varied from 88% to 100%, while their
specificity varied from 56% to 83%. The sensitivity of the NASBA-
OC study was 88.6% and its specificity was 14.3%.
Discussion
Molecular tests have been proposed as sensitive diagnostic tools
for HAT; however, the accuracy of these tests for diagnosis has not
yet been fully verified. In this systematic review, we analyzed the
data from all available accuracy studies on molecular amplification
tests for HAT, in order to better guide adoption of these tests in
practice as possible triage, replacement or supportive diagnostic
tests. From the available literature, conclusions can only be drawn
about the accuracy of PCR tests for the diagnosis of HAT in
blood. Overall, the 11 studies that analyzed PCR tests (both PCR
and PCR-OC) on blood showed a high summary sensitivity of
99.0% and a specificity of 97.7%. Insufficient evidence was
available about the accuracy of other molecular tests or about the
ability of molecular tests to distinguish between stage I and stage II
HAT.
More insight into the optimal place of PCR in practice and the
types of PCR that can be used can be gained by the results of our
subgroup-analyses. One source of variation that had a significant
effect on diagnostic accuracy of PCR for HAT was the target
DNA sequence of the test. Studies that used satellite DNA as target
sequence showed significantly lower specificity than studies that
used other target sequences. The satellite DNA target is highly
specific and conserved among the Trypanozoon of which two
subspecies of Trypanosoma brucei cause HAT [12]. The lower
specificity may be due to contamination problems during DNA
collection, extraction or amplification or inoculations with T. b.
brucei which can circulate in blood of people with a regular
challenge to tsetse fly bites [33]. It can also be caused by the design
of the studies where we see more representative patient groups as
compared with other studies. In addition, we do expect to see a
high number of false positives if the reference test (here PCR on
satellite DNA) is more sensitive than the index test.
Figure 3. Forest plots. Overview of all 2 by 2 tables with forest plot (TP=true positives; FP=false positives; FN=false negatives; TN=true
negatives; CSF=cerebrospinal fluid; PCR=polymerase chain reaction; NASBA=nucleic acid sequence based amplification; OC=oligochromato-
graphy; RT=real-time). Capital A or B refers to different set of data from the same paper. These sets may differ in clinical specimen studied, target
gene or amplification technology applied.
doi:10.1371/journal.pntd.0001438.g003
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for their significance due to too few studies, such as sub-species
detected and clinical sample used. The type of read-out system,
(e.g. gel electrophoresis, OC) did not seem to affect accuracy. We
found only one study analysing PCR diagnosis of T. b. rhodesiense.
Accuracy results from T. b. gambiense can not necessarily be
generalised for this sub-species and we recommend further
diagnostic accuracy studies for T. b. rhodesiense. However, the
parasitaemia for T. b. rhodesiense is generally higher than that of T.
b. gambiense and disease progression is faster. We may, therefore,
expect that molecular tools would have a high accuracy as more
parasite DNA is present in blood samples [34]. Of all studies
included, five, analyzed molecular tests in CSF; only one of these
used CSF for primary diagnosis. Therefore, no firm conclusion
can be drawn regarding the difference between blood and CSF for
diagnosing HAT.
Three studies evaluated the ability of PCR to diagnose stage II
HAT using CSF [22,24,25]. Routinely, staging is performed by
microscopic examination of CSF samples that are obtained by
lumbar puncture of confirmed HAT patients. The CSF is
examined for presence of trypanosomes and elevated white
blood cell count .5 cells/ml [28,35]. The sensitivity of PCR to
distinguish between stage I and stage II HAT ranged from 88%
to100% and its specificity ranged from 56% to 83%. Although the
number of false positives and false negatives in each study is
variable and strong conclusions can not be made, the percentages
of false positives is concerning, as these patients would be treated
with a high risk treatment and may not have stage II HAT.
Lumbar puncture remains inevitable as staging is paramount given
that the different stages of HAT are managed using different drugs
and is required for both molecular and microscopic staging of
disease [34,36]. The difficulty in diagnosing stage II HAT
reiterates the need for prompt and accurate diagnosis of stage I
HAT.
Limitations
Our results suffer from two main limitations, one regarding the
representativeness of the included patients and the other regarding
the reference standard. Of the 11 studies in our main analysis
(accuracy of PCR tests), only four included a representative patient
spectrum. This may be a threat for the validity of the results shown
here and for the translation of the results into practice. Diagnostic
accuracy is not a fixed property of a test and may change over
populations, especially when these populations are suffering from
selection bias [19,37,38]. The most severe form of selection bias is
using a case-control design in which the cases are confirmed and
known cases and the controls are healthy people. Four out of
eleven PCR studies were case-control studies and these showed a
significantly higher specificity, which is expected as the included
healthy controls are known to lead to an overestimation of
accuracy [39,40]. Future studies should think carefully about the
patients to include and choose the patient spectrum most closely
matching the situation as found in practice, otherwise health
workers are forced to rely on accuracy data that are not
representative. We recommend the inclusion of clinically or
serologically suspected persons; e.g. persons living in endemic
Figure 4. Raw ROC plot. Summary ROC plot for PCR and PCR-OC.
Shows summary estimate (black dot), summary curve and confidence
ellipse around the summary estimate. Width of the symbols reflects the
number of non-diseased patients; height of the symbol reflects the
number of diseased patients.
doi:10.1371/journal.pntd.0001438.g004
Table 2. Meta-analysis for PCR tests completed on blood, including subgroup analyses.
Main analysis Studies (n) Sensitivity (95% CI) Specificity (95% CI)
PCR and PCR-OC combined 11 99.0% (92.8 to 99.9%) 97.7% (93.0 to 99.3%)
Subgroup analysis Studies (n) Sensitivity (95% CI) Specificity (95% CI)
PCR 9 99.1% (93.8 to 99.9%) 97.4% (91.4 to 99.2%)
PCR-OC 2 96.5% (46.5 to 99.9%) 99.0% (86.7 to 99.9%)
p-value 0.471 0.506
PCR test on blood, satellite gene 5 99.1% (93.0 to 99.9%) 91.4% (82.6 to 96.0%)
PCR test on blood, other target genes 6 97.6% (85.7 to 99.6%) 99.5% (97.5 to 99.9%)
p-value 0.428 0.002
PCR test on blood, case-control studies 4 98.7% (82.9 to 99.9%) 99.8% (95.5 to 100%)
PCR test on blood, non-case-control studies 7 98.6% (90.7 to 99.8%) 94.5% (86.8 to 97.8%)
p-value 0.937 0.045
OC: Oligochromatography.
doi:10.1371/journal.pntd.0001438.t002
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other neurological symptoms or positive in a serological test.
The other limitation of the studies that are presently available is
that most use microscopy as the reference standard. Microscopy,
itself, may have a relatively low sensitivity, although most of the
studies we included used a form of centrifugation in order to
increase sensitivity [34,41]. However, the highly toxic treatment
administered to HAT patients should only be given after
demonstration of the parasites, and therefore, microscopy remains
the accepted reference standard for HAT. For this review it means
that sensitivity is the percentage of microscopy-positive patients
with a positive molecular test and specificity is the percentage of
microscopy-negative patients with a negative molecular test. In
reality, it is possible that the index tests have correctly diagnosed
patients who have been missed by microscopy due to its low
sensitivity. In such cases the accuracy, and especially the
specificity, of the index test is underestimated. However, in
diagnostic studies, if there are any disagreements between the
reference standard and the index test then it is assumed that the
index test is incorrect. Therefore, in diagnostic accuracy study
designs the index tests, by definition, can never be better than the
reference standard. Other study designs or analytic techniques are
needed to get more information about the relative accuracy of
PCR versus microscopy. Examples may be latent class analyses,
decision analyses or longitudinal studies using another reference
standard to compare both PCR and microscopy with [42].
Even if the accuracy of PCR tests may be close to perfect,
implementation of molecular diagnostic tests in the low and
middle income countries that are most affected by HAT will be a
difficult and arduous task. Role-out could be hampered by more
practical issues; the time it may take before a diagnosis is made, the
need for a cold-chain, continuous electricity or expertly-trained
staff. Development of simple and more appropriate molecular
tests, such as LAMP, that may show the same high accuracy in due
course, may be a solution. For now, an important role for PCR in
the control of HAT may be in screening samples from serologically
positive patients collected from the field in a central reference
laboratory; the high accuracy, shown here, would allow epidemics
of HAT to be spotted early and treatment directed towards these
specific areas. Longitudinal impact studies, feasibility studies and
cost-effectiveness studies may be warranted to gain further
information about the practical application of molecular diagnos-
tics for HAT and their position within the diagnostic algorithm.
In conclusion, PCR tests seem to have an acceptably high
specificity and sensitivity for diagnosis of stage I HAT. This
conclusion is, however, based on microscopy as reference standard
and a patient population that was not always representative.
Future studies should, therefore, first and foremost include those
patients for which PCR may become the test of choice. More
certainty about the practical value of PCR tests for HAT diagnosis
should come from non-accuracy design studies, like feasibility or
cost-effectiveness studies.
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